diabetestalk.net

Experiencing The MiniMed 670G System After 43 Years With Diabetes

Experiencing the MiniMed 670G System after 43 Years with Diabetes

Experiencing the MiniMed 670G System after 43 Years with Diabetes

In March, we shipped the MiniMed 670G systems to customers in the Customer Training Phase. Among them is Laura, Medtronic Clinical Specialist in Phoenix, Arizona, who has been a part of the Medtronic family – both as a Certified Product Trainer and employee – for 26 years. Today, she shares her experience with the new system.
I’ve been on the MiniMed 670G system for a month, and haven’t felt this good in 43 years living with diabetes. I love it!
When the FDA approved the MiniMed 670G system, I cried tears of joy. I couldn’t believe this day had finally come.
Insulin pumps and continuous glucose monitors (CGM) are a huge part of my personal and professional life. Watching and personally experiencing the advancements in pump and sensor technology has been amazing. My first insulin pump in 1980 weighed a whopping 2.7 pounds (in comparison, the MiniMed 670G system is 1/5 pound)!
After 43 years of living with diabetes and 37 years pumping, I’m ecstatic to be on this journey with the world’s first hybrid closed loop system – the MiniMed 670G system!
I live an active lifestyle, and no day is the same. For people with diabetes, this means insulin needs vary each day. I love that the MiniMed 670G system understands this – getting to know my insulin needs more every day, and automatically adjusts and personalizes insulin delivery 24 hours a day.
I’ve struggled with hypoglycemia unawareness for many years, and the new Suspend before low feature – to me – is a miracle! Suspend before low kept me from going low four times in the three days before I turned on Auto Continue reading

Rate this article
Total 1 ratings
Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)

Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)

Abstract
Objective To compare the effectiveness of insulin pumps with multiple daily injections for adults with type 1 diabetes, with both groups receiving equivalent training in flexible insulin treatment.
Design Pragmatic, multicentre, open label, parallel group, cluster randomised controlled trial (Relative Effectiveness of Pumps Over MDI and Structured Education (REPOSE) trial).
Setting Eight secondary care centres in England and Scotland.
Participants Adults with type 1 diabetes who were willing to undertake intensive insulin treatment, with no preference for pumps or multiple daily injections. Participants were allocated a place on established group training courses that taught flexible intensive insulin treatment (“dose adjustment for normal eating,” DAFNE). The course groups (the clusters) were then randomly allocated in pairs to either pump or multiple daily injections.
Interventions Participants attended training in flexible insulin treatment (using insulin analogues) structured around the use of pump or injections, followed for two years.
Main outcome measures The primary outcomes were a change in glycated haemoglobin (HbA1c) values (%) at two years in participants with baseline HbA1c value of ≥7.5% (58 mmol/mol), and the proportion of participants achieving an HbA1c value of <7.5%. Secondary outcomes included body weight, insulin dose, and episodes of moderate and severe hypoglycaemia. Ancillary outcomes included quality of life and treatment satisfaction.
Results 317 participants (46 courses) were randomised (156 pump and 161 injections). 267 attended cou Continue reading

NIHR Signal Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes

NIHR Signal Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes

People with type 1 diabetes offered insulin pumps did not achieve better blood glucose control compared with those using multiple daily injections. Education remains important.
While both groups saw improvements in blood glucose levels and fewer hypoglycaemic episodes (very low blood sugar) over two years, only one in four participants met NICE blood glucose targets. Insulin pump users showed some modest improvements in satisfaction, dietary freedom and daily hassle.
All participants in this NIHR trial attended a training course on managing their insulin levels before randomisation. This is important because previously observed benefits from pump treatment might actually have been a reflection of the training given to them.
Currently just 10% of adults with type 1 diabetes access these training courses. These results support NICE guidelines around the restricted use of insulin pumps and suggest that training improves self-management of the condition. Efforts should therefore be made to encourage training uptake.
People with type 1 diabetes require lifelong treatment with insulin. Doses are adjusted according to food intake, physical activity, and blood glucose level. High or low blood glucose levels lead to serious short and long term complications, however, many people struggle to maintain blood glucose levels within the target range.
Insulin pumps are small devices, about the size of a mobile phone, that deliver a steady flow of insulin. They offer an alternative to multiple daily injections, and may also help people who are unable to achieve blood glucose control. They a Continue reading

U.S. Diabetes Patients Are About to Get Some High-Tech Relief

U.S. Diabetes Patients Are About to Get Some High-Tech Relief

User-friendly devices to replace old, ‘barbaric’ tools
‘This is a crossroads for diabetes technology:’ analyst
Diabetes devices may be having their iPhone moment.
For decades, the daily routine of diabetics involved painful needles, finger-pricking lancets and imprecise glucose meters. Now, manufacturers have begun incorporating the slick and consumer-friendly designs of Silicon Valley, linking to phones and other tech devices.
“This is a crossroads for diabetes technology,’’ said Raj Denhoy, an analyst at Jefferies in New York.
September marked a breakthrough in the U.S., as regulators approved the first glucose-monitoring system that doesn’t need a blood sample, the FreeStyle Libre by Abbott Laboratories. The new devices do away with fingerpricks, changing an unpleasant, several-times-a-day routine into quiet monitoring in the background through a sensor worn on the back of the upper arm.
Other companies have been left behind. Johnson & Johnson is closing its insulin-pump unit after failing to keep up with Medtronic Plc. DexCom Inc., the current leader in glucose-monitoring systems, lost a third of its market value on Sept. 28 after Abbott’s Libre got approval.
On DexCom’s earnings conference call Wednesday executives, peppered with questions about the Libre, said the company hopes to introduce its own fingerprick-free device before the end of 2018. The comments about next-generation monitors helped assuage investors’ concerns about DexCom’s prospects, sending the stock up 9.5 percent in the two trading days following the results.
“Companies who Continue reading

Diabetes Technology Moves Closer To Making Life Easier For Patients

Diabetes Technology Moves Closer To Making Life Easier For Patients

For people with diabetes, keeping blood sugar levels in a normal range – not too high or too low – is a lifelong challenge. New technologies to ease the burden are emerging rapidly, but insurance reimbursement challenges, supply shortages, and shifting competition make it tough for patients to access them quickly.
One new product is a fast-acting insulin from Novo Nordisk. It is designed to help to minimize the high blood sugar spikes that often occur when people with diabetes eat a meal containing carbohydrates.
This new formulation, branded "Fiasp," adds niacinamide (vitamin B3), which roughly doubles the speed of initial insulin absorption compared to current fast-acting insulins taken at mealtime. This new insulin hits the bloodstream in under three minutes.
Another advance is Abbott's new monitoring device called the FreeStyle Libre Flash. It's new in the U.S. but has been available in Europe since 2014. It's a round patch with a catheter that is inserted on the arm for up to 10 days and a durable scanning device that the user waves over the patch to read the level of sugar in their tissues, which reflects the blood sugar level.
The Libre works a bit differently than the two currently available continuous glucose monitors (CGMs) made by Dexcom and Medtronic. The Libre doesn't require users to prick their fingers for blood tests to calibrate it, whereas users of the other monitors must perform twice-daily fingerstick calibrations.
Also, the Libre is approved for longer wear – 10 days (14 in Europe) versus seven days for the two current CGMs. And, it is likely to b Continue reading

No more pages to load

Popular Articles

  • Boy with diabetes saves pennies for 4 years to get service dog
    Boy with diabetes saves pennies for 4 years to get service dog

    WAITSFIELD, Vermont -- Eight-year-old Aiden Heath has spent a little over four years collecting loose change with a goal in mind. And that dedication paid off this week when he finally came face-to-snout with his very own service dog, Angel. "Aiden looked at me and said, 'This is a dream,'" his mother, Jenni Heath, told ABC News. Aiden, of Waitsfield, Vermont, was diagnosed with type 1 diabetes fo ...

  • Cost Of Diabetes Has Doubled In Past 20 Years
    Cost Of Diabetes Has Doubled In Past 20 Years

    According to new research from the Centers for Disease Control and Prevention (CDC), managing diabetes may be twice as expensive as it was 20 years ago. Patients now spend about $2,790 more per year on diabetes-associated costs than in 1987. The study found that over 50 percent of annual diabetes-associated costs is spent on prescription medications. 24 percent is spent on inpatient visits, 15 per ...

  • Boy with diabetes saves pennies for 4 years to get service dog
    Boy with diabetes saves pennies for 4 years to get service dog

    WAITSFIELD, Vermont -- Eight-year-old Aiden Heath has spent a little over four years collecting loose change with a goal in mind. And that dedication paid off this week when he finally came face-to-snout with his very own service dog, Angel. "Aiden looked at me and said, 'This is a dream,'" his mother, Jenni Heath, told ABC News. Aiden, of Waitsfield, Vermont, was diagnosed with type 1 diabetes fo ...

  • City of Hope's New Approach Aims to Cure Type 1 Diabetes in Six Years
    City of Hope's New Approach Aims to Cure Type 1 Diabetes in Six Years

    CITY OF HOPE SETS NEW GOAL FOR TYPE 1 DIABETES CURE More than $50 million in private funding aims to cure Type 1 diabetes in six years A recent grouping of donations totaling $50 million is outstanding, those in the trenches with diabetes said. But only six years to a cure? Really? You lost us there, some claimed. Dr. Bart Roep, Ph.D., director of the program, now known as the Wanek Family Pr ...

  • How Does Diabetes Affect the Digestive System?
    How Does Diabetes Affect the Digestive System?

    If you’ve recently been diagnosed with diabetes or have been living with the disease for a while, you’re more than likely familiar with possible complications, like kidney disease, vision loss, and even amputations. But it’s important to note that poorly controlled type 2 diabetes can also affect other parts of your body, including your digestive system, and that the longer you’ve lived wi ...

  • How Does Diabetes Affect the Immune System?
    How Does Diabetes Affect the Immune System?

    Diabetes, as we know, is a complicated disorder. When you have diabetes, there is a host of other diseases that you will be exposed to including cardiovascular diseases, kidney-related conditions, and others. However, diabetes also weakens the immunity system of the patient’s body. It is a metabolic disorder that exposes you to various unwanted infections and other conditions. In this article, w ...

  • FDA Approves The First Automated Insulin System For Type 1 Diabetes
    FDA Approves The First Automated Insulin System For Type 1 Diabetes

    The Food and Drug Administration's approval of a new insulin delivery system for people with Type 1 diabetes is a big deal. With Type 1 diabetes, the pancreas makes little or no insulin so people have to replace it with either multiple daily injections or a pump. In either case, that process involves constant error-prone adjustments, particularly around food and exercise. Over the long term, high ...

  • The Plant That Kills Cancer Cells, Stop Diabetes and Boosts Your Immune System!
    The Plant That Kills Cancer Cells, Stop Diabetes and Boosts Your Immune System!

    Goya, or otherwise known as Karela, is a “bitter-melon” fruit that has been used for health benefits in countries all over the world for a long period of time. It grows well in humid and hot climates and can be mostly found in South America and Asia. It is a common traditional medicine in China, India, Asia and some southeastern parts of US. This healthy melon has an extremely bitter taste, an ...

  • The Plant That Kills Cancer Cells, Stops Diabetes And Boosts Your Immune System!
    The Plant That Kills Cancer Cells, Stops Diabetes And Boosts Your Immune System!

    Bitter melon or karela is a plant that has been used as a natural antidiabetic by some indigenous populations, and it is a true gift from nature and a great aid for people suffering from malignant diseases. Scientific studies showed that this plant can actually serve as a cure for certain types of cancer due to the active ingredients which prevent the metabolism of glucose in malignant cells and ...

Related Articles